Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O8JB
|
|||
| Former ID |
DAP001296
|
|||
| Drug Name |
Secretin
|
|||
| Synonyms |
SECREFLO; SecreFlow; Secrepan; Secretina; Secretine; Secretinum; Secretolin; Vitrum; Hormone of the duodenal mucosa that activates pancreatic secretion and lowers the blood sugar level; Human secretin; RG 1068; L-Valinamide; SECRETIN-FERRING; Secretin (human); Secretin (porcine); Secretin-Kabi; Secretina [INN-Spanish]; Secretine [INN-French]; Secretinum [INN-Latin]; Secretin [INN:BAN:DCF:JAN]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gastrinoma [ICD-11: 2C10.1] | Approved | [1], [2], [3] | |
| Pancreatic exocrine dysfunction [ICD-11: DC3Z] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Diagnostic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C130H219N43O42
|
|||
| Canonical SMILES |
CC(C)CC(C(=O)NC(C(C)C)C(=O)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(CC2=NC=CN2)N
|
|||
| InChI |
1S/C130H219N43O42/c1-59(2)43-78(118(206)172-99(65(13)14)126(214)215)151-94(182)53-148-104(192)75(31-34-91(132)180)156-113(201)81(46-62(7)8)163-115(203)82(47-63(9)10)161-107(195)72(28-22-38-145-128(136)137)153-110(198)76(32-35-92(133)181)157-114(202)80(45-61(5)6)159-106(194)71(27-21-37-144-127(134)135)152-102(190)66(15)150-120(208)87(55-174)168-117(205)86(52-98(188)189)165-109(197)73(29-23-39-146-129(138)139)154-112(200)79(44-60(3)4)160-108(196)74(30-24-40-147-130(140)141)155-121(209)89(57-176)169-116(204)83(48-64(11)12)162-111(199)77(33-36-96(184)185)158-122(210)90(58-177)170-125(213)101(68(17)179)173-119(207)84(49-69-25-19-18-20-26-69)166-124(212)100(67(16)178)171-95(183)54-149-105(193)85(51-97(186)187)164-123(211)88(56-175)167-103(191)70(131)50-93-142-41-42-143-93/h18-20,25-26,41-42,59-68,70-90,99-101,174-179H,21-24,27-40,43-58,131H2,1-17H3,(H2,132,180)(H2,133,181)(H,142,143)(H,148,192)(H,149,193)(H,150,208)(H,151,182)(H,152,190)(H,153,198)(H,154,200)(H,155,209)(H,156,201)(H,157,202)(H,158,210)(H,159,194)(H,160,196)(H,161,195)(H,162,199)(H,163,203)(H,164,211)(H,165,197)(H,166,212)(H,167,191)(H,168,205)(H,169,204)(H,170,213)(H,171,183)(H,172,206)(H,173,207)(H,184,185)(H,186,187)(H,188,189)(H,214,215)(H4,134,135,144)(H4,136,137,145)(H4,138,139,146)(H4,140,141,147)
|
|||
| InChIKey |
KKNIUBFRGPFELP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1393-25-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D01999 ; BADD_D02000 | |||
| SuperDrug ATC ID |
V04CK01
|
|||
| SuperDrug CAS ID |
cas=001393255
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Secretin receptor (SCT) | Target Info | Binder | [4] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Pancreatic secretion | ||||
| Bile secretion | ||||
| Reactome | G alpha (s) signalling events | |||
| Glucagon-type ligand receptors | ||||
| WikiPathways | GPCRs, Class B Secretin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3644). | |||
| REF 2 | 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. | |||
| REF 3 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021209. | |||
| REF 4 | False-positive secretin stimulation test for gastrinoma associated with the use of proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2009 May;7(5):600-2. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.